ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global GLP-1 Agonists for Obesity Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-6Q17184
Home | Market Reports | Health| Health Conditions| Obesity
Global GLP 1 Agonists for Obesity Market Research Report 2024
BUY CHAPTERS

Global GLP-1 Agonists for Obesity Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-6Q17184
Report
November 2025
Pages:114
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novo Nordisk
Eli Lilly
Huadong Medicine
Shanghai Benemae Pharmaceutical Corporation

GLP-1 Agonists for Obesity Market

The global GLP-1 Agonists for Obesity market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
GLP-1 (glucagon-like peptide-1) agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. Some GLP-1 agonists have been approved to help treat obesity. GLP-1 agonists have been shown to be effective in promoting weight loss in preclinical and clinical studies.
From a downstream perspective, Hospital Pharmaty accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
GLP-1 Agonists for Obesity leading manufacturers including Novo Nordisk, Eli Lilly, Huadong Medicine, Shanghai Benemae Pharmaceutical Corporation, etc., dominate supply; the top five capture approximately % of global revenue, with Novo Nordisk leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global GLP-1 Agonists for Obesity market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of GLP-1 Agonists for Obesity Market Report

Report Metric Details
Report Name GLP-1 Agonists for Obesity Market
Segment by Type
  • Semaglutide
  • Tirzepatide
  • Liraglutide
  • Benaglutide
Segment by Application
  • Hospital Pharmaty
  • Retail Pharmaty
  • Others
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Novo Nordisk, Eli Lilly, Huadong Medicine, Shanghai Benemae Pharmaceutical Corporation
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the GLP-1 Agonists for Obesity study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the GLP-1 Agonists for Obesity Market report?

Ans: The main players in the GLP-1 Agonists for Obesity Market are Novo Nordisk, Eli Lilly, Huadong Medicine, Shanghai Benemae Pharmaceutical Corporation

What are the Application segmentation covered in the GLP-1 Agonists for Obesity Market report?

Ans: The Applications covered in the GLP-1 Agonists for Obesity Market report are Hospital Pharmaty, Retail Pharmaty, Others

What are the Type segmentation covered in the GLP-1 Agonists for Obesity Market report?

Ans: The Types covered in the GLP-1 Agonists for Obesity Market report are Semaglutide, Tirzepatide, Liraglutide, Benaglutide

1 Study Coverage
1.1 Introduction to GLP-1 Agonists for Obesity: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global GLP-1 Agonists for Obesity Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Semaglutide
1.2.3 Tirzepatide
1.2.4 Liraglutide
1.2.5 Benaglutide
1.3 Market Segmentation by Application
1.3.1 Global GLP-1 Agonists for Obesity Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmaty
1.3.3 Retail Pharmaty
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global GLP-1 Agonists for Obesity Revenue Estimates and Forecasts 2020-2031
2.2 Global GLP-1 Agonists for Obesity Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global GLP-1 Agonists for Obesity Sales Estimates and Forecasts 2020-2031
2.4 Global GLP-1 Agonists for Obesity Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global GLP-1 Agonists for Obesity Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global GLP-1 Agonists for Obesity Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Semaglutide Market Size by Manufacturers
3.5.2 Tirzepatide Market Size by Manufacturers
3.5.3 Liraglutide Market Size by Manufacturers
3.5.4 Benaglutide Market Size by Manufacturers
3.6 Global GLP-1 Agonists for Obesity Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global GLP-1 Agonists for Obesity Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global GLP-1 Agonists for Obesity Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global GLP-1 Agonists for Obesity Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global GLP-1 Agonists for Obesity Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America GLP-1 Agonists for Obesity Sales and Revenue by Type (2020-2031)
6.4 North America GLP-1 Agonists for Obesity Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America GLP-1 Agonists for Obesity Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe GLP-1 Agonists for Obesity Sales and Revenue by Type (2020-2031)
7.4 Europe GLP-1 Agonists for Obesity Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe GLP-1 Agonists for Obesity Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific GLP-1 Agonists for Obesity Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific GLP-1 Agonists for Obesity Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific GLP-1 Agonists for Obesity Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America GLP-1 Agonists for Obesity Sales and Revenue by Type (2020-2031)
9.4 Central and South America GLP-1 Agonists for Obesity Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America GLP-1 Agonists for Obesity Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa GLP-1 Agonists for Obesity Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa GLP-1 Agonists for Obesity Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa GLP-1 Agonists for Obesity Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Novo Nordisk
11.1.1 Novo Nordisk Corporation Information
11.1.2 Novo Nordisk Business Overview
11.1.3 Novo Nordisk GLP-1 Agonists for Obesity Product Models, Descriptions and Specifications
11.1.4 Novo Nordisk GLP-1 Agonists for Obesity Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Novo Nordisk GLP-1 Agonists for Obesity Sales by Product in 2024
11.1.6 Novo Nordisk GLP-1 Agonists for Obesity Sales by Application in 2024
11.1.7 Novo Nordisk GLP-1 Agonists for Obesity Sales by Geographic Area in 2024
11.1.8 Novo Nordisk GLP-1 Agonists for Obesity SWOT Analysis
11.1.9 Novo Nordisk Recent Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Corporation Information
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly GLP-1 Agonists for Obesity Product Models, Descriptions and Specifications
11.2.4 Eli Lilly GLP-1 Agonists for Obesity Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Eli Lilly GLP-1 Agonists for Obesity Sales by Product in 2024
11.2.6 Eli Lilly GLP-1 Agonists for Obesity Sales by Application in 2024
11.2.7 Eli Lilly GLP-1 Agonists for Obesity Sales by Geographic Area in 2024
11.2.8 Eli Lilly GLP-1 Agonists for Obesity SWOT Analysis
11.2.9 Eli Lilly Recent Developments
11.3 Huadong Medicine
11.3.1 Huadong Medicine Corporation Information
11.3.2 Huadong Medicine Business Overview
11.3.3 Huadong Medicine GLP-1 Agonists for Obesity Product Models, Descriptions and Specifications
11.3.4 Huadong Medicine GLP-1 Agonists for Obesity Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Huadong Medicine GLP-1 Agonists for Obesity Sales by Product in 2024
11.3.6 Huadong Medicine GLP-1 Agonists for Obesity Sales by Application in 2024
11.3.7 Huadong Medicine GLP-1 Agonists for Obesity Sales by Geographic Area in 2024
11.3.8 Huadong Medicine GLP-1 Agonists for Obesity SWOT Analysis
11.3.9 Huadong Medicine Recent Developments
11.4 Shanghai Benemae Pharmaceutical Corporation
11.4.1 Shanghai Benemae Pharmaceutical Corporation Corporation Information
11.4.2 Shanghai Benemae Pharmaceutical Corporation Business Overview
11.4.3 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Product Models, Descriptions and Specifications
11.4.4 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Sales by Product in 2024
11.4.6 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Sales by Application in 2024
11.4.7 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Sales by Geographic Area in 2024
11.4.8 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity SWOT Analysis
11.4.9 Shanghai Benemae Pharmaceutical Corporation Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 GLP-1 Agonists for Obesity Industry Chain
12.2 GLP-1 Agonists for Obesity Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 GLP-1 Agonists for Obesity Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 GLP-1 Agonists for Obesity Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 GLP-1 Agonists for Obesity Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global GLP-1 Agonists for Obesity Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Novo Nordisk
Eli Lilly
Huadong Medicine
Shanghai Benemae Pharmaceutical Corporation
List of Tables
 Table 1. Global GLP-1 Agonists for Obesity Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global GLP-1 Agonists for Obesity Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global GLP-1 Agonists for Obesity Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global GLP-1 Agonists for Obesity Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global GLP-1 Agonists for Obesity Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global GLP-1 Agonists for Obesity Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Dose)
 Table 7. Global GLP-1 Agonists for Obesity Sales by Region (2020-2025) & (K Dose)
 Table 8. Global GLP-1 Agonists for Obesity Sales by Region (2026-2031) & (K Dose)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global GLP-1 Agonists for Obesity Sales by Manufacturers (2020-2025) & (K Dose)
 Table 11. Global GLP-1 Agonists for Obesity Sales Share by Manufacturers (2020-2025)
 Table 12. Global GLP-1 Agonists for Obesity Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global GLP-1 Agonists for Obesity Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global GLP-1 Agonists for Obesity by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in GLP-1 Agonists for Obesity as of 2024)
 Table 16. Global GLP-1 Agonists for Obesity Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global GLP-1 Agonists for Obesity Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Dose)
 Table 18. Key Manufacturers GLP-1 Agonists for Obesity Manufacturing Base and Headquarters
 Table 19. Global GLP-1 Agonists for Obesity Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global GLP-1 Agonists for Obesity Sales by Type (2020-2025) & (K Dose)
 Table 23. Global GLP-1 Agonists for Obesity Sales by Type (2026-2031) & (K Dose)
 Table 24. Global GLP-1 Agonists for Obesity Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global GLP-1 Agonists for Obesity Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global GLP-1 Agonists for Obesity ASP by Type (2020-2031) & (US$/Dose)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global GLP-1 Agonists for Obesity Sales by Application (2020-2025) & (K Dose)
 Table 29. Global GLP-1 Agonists for Obesity Sales by Application (2026-2031) & (K Dose)
 Table 30. GLP-1 Agonists for Obesity High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global GLP-1 Agonists for Obesity Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global GLP-1 Agonists for Obesity Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global GLP-1 Agonists for Obesity ASP by Application (2020-2031) & (US$/Dose)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America GLP-1 Agonists for Obesity Growth Accelerators and Market Barriers
 Table 37. North America GLP-1 Agonists for Obesity Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America GLP-1 Agonists for Obesity Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe GLP-1 Agonists for Obesity Growth Accelerators and Market Barriers
 Table 40. Europe GLP-1 Agonists for Obesity Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe GLP-1 Agonists for Obesity Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific GLP-1 Agonists for Obesity Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific GLP-1 Agonists for Obesity Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific GLP-1 Agonists for Obesity Growth Accelerators and Market Barriers
 Table 45. Southeast Asia GLP-1 Agonists for Obesity Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America GLP-1 Agonists for Obesity Investment Opportunities and Key Challenges
 Table 47. Central and South America GLP-1 Agonists for Obesity Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa GLP-1 Agonists for Obesity Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa GLP-1 Agonists for Obesity Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Novo Nordisk Corporation Information
 Table 51. Novo Nordisk Description and Major Businesses
 Table 52. Novo Nordisk Product Models, Descriptions and Specifications
 Table 53. Novo Nordisk Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 54. Novo Nordisk Sales Value Proportion by Product in 2024
 Table 55. Novo Nordisk Sales Value Proportion by Application in 2024
 Table 56. Novo Nordisk Sales Value Proportion by Geographic Area in 2024
 Table 57. Novo Nordisk GLP-1 Agonists for Obesity SWOT Analysis
 Table 58. Novo Nordisk Recent Developments
 Table 59. Eli Lilly Corporation Information
 Table 60. Eli Lilly Description and Major Businesses
 Table 61. Eli Lilly Product Models, Descriptions and Specifications
 Table 62. Eli Lilly Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 63. Eli Lilly Sales Value Proportion by Product in 2024
 Table 64. Eli Lilly Sales Value Proportion by Application in 2024
 Table 65. Eli Lilly Sales Value Proportion by Geographic Area in 2024
 Table 66. Eli Lilly GLP-1 Agonists for Obesity SWOT Analysis
 Table 67. Eli Lilly Recent Developments
 Table 68. Huadong Medicine Corporation Information
 Table 69. Huadong Medicine Description and Major Businesses
 Table 70. Huadong Medicine Product Models, Descriptions and Specifications
 Table 71. Huadong Medicine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 72. Huadong Medicine Sales Value Proportion by Product in 2024
 Table 73. Huadong Medicine Sales Value Proportion by Application in 2024
 Table 74. Huadong Medicine Sales Value Proportion by Geographic Area in 2024
 Table 75. Huadong Medicine GLP-1 Agonists for Obesity SWOT Analysis
 Table 76. Huadong Medicine Recent Developments
 Table 77. Shanghai Benemae Pharmaceutical Corporation Corporation Information
 Table 78. Shanghai Benemae Pharmaceutical Corporation Description and Major Businesses
 Table 79. Shanghai Benemae Pharmaceutical Corporation Product Models, Descriptions and Specifications
 Table 80. Shanghai Benemae Pharmaceutical Corporation Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 81. Shanghai Benemae Pharmaceutical Corporation Sales Value Proportion by Product in 2024
 Table 82. Shanghai Benemae Pharmaceutical Corporation Sales Value Proportion by Application in 2024
 Table 83. Shanghai Benemae Pharmaceutical Corporation Sales Value Proportion by Geographic Area in 2024
 Table 84. Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity SWOT Analysis
 Table 85. Shanghai Benemae Pharmaceutical Corporation Recent Developments
 Table 86. Key Raw Materials Distribution
 Table 87. Raw Materials Key Suppliers
 Table 88. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 89. Milestones in Production Technology Evolution
 Table 90. Distributors List
 Table 91. Market Trends and Market Evolution
 Table 92. Market Drivers and Opportunities
 Table 93. Market Challenges, Risks, and Restraints
 Table 94. Research Programs/Design for This Report
 Table 95. Key Data Information from Secondary Sources
 Table 96. Key Data Information from Primary Sources


List of Figures
 Figure 1. GLP-1 Agonists for Obesity Product Picture
 Figure 2. Global GLP-1 Agonists for Obesity Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Semaglutide Product Picture
 Figure 4. Tirzepatide Product Picture
 Figure 5. Liraglutide Product Picture
 Figure 6. Benaglutide Product Picture
 Figure 7. Global GLP-1 Agonists for Obesity Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 8. Hospital Pharmaty
 Figure 9. Retail Pharmaty
 Figure 10. Others
 Figure 11. GLP-1 Agonists for Obesity Report Years Considered
 Figure 12. Global GLP-1 Agonists for Obesity Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global GLP-1 Agonists for Obesity Revenue (2020-2031) & (US$ Million)
 Figure 14. Global GLP-1 Agonists for Obesity Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 15. Global GLP-1 Agonists for Obesity Revenue Market Share by Region (2020-2031)
 Figure 16. Global GLP-1 Agonists for Obesity Sales (2020-2031) & (K Dose)
 Figure 17. Global GLP-1 Agonists for Obesity Sales (CAGR) by Region (2020-2031) (K Dose)
 Figure 18. Global GLP-1 Agonists for Obesity Sales Market Share by Region (2020-2031)
 Figure 19. Top 5 and Top 10 Manufacturers GLP-1 Agonists for Obesity Sales Volume Market Share in 2024
 Figure 20. Global GLP-1 Agonists for Obesity Revenue Market Share Ranking (2024)
 Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 22. Semaglutide Revenue Market Share by Manufacturer in 2024
 Figure 23. Tirzepatide Revenue Market Share by Manufacturer in 2024
 Figure 24. Liraglutide Revenue Market Share by Manufacturer in 2024
 Figure 25. Benaglutide Revenue Market Share by Manufacturer in 2024
 Figure 26. Global GLP-1 Agonists for Obesity Sales Market Share by Type (2020-2031)
 Figure 27. Global GLP-1 Agonists for Obesity Revenue Market Share by Type (2020-2031)
 Figure 28. Global GLP-1 Agonists for Obesity Sales Market Share by Application (2020-2031)
 Figure 29. Global GLP-1 Agonists for Obesity Revenue Market Share by Application (2020-2031)
 Figure 30. North America GLP-1 Agonists for Obesity Sales YoY (2020-2031) & (K Dose)
 Figure 31. North America GLP-1 Agonists for Obesity Revenue YoY (2020-2031) & (US$ Million)
 Figure 32. North America Top 5 Manufacturers GLP-1 Agonists for Obesity Sales Revenue (US$ Million) in 2024
 Figure 33. North America GLP-1 Agonists for Obesity Sales Volume (K Dose) by Type (2020- 2031)
 Figure 34. North America GLP-1 Agonists for Obesity Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 35. North America GLP-1 Agonists for Obesity Sales Volume (K Dose) by Application (2020-2031)
 Figure 36. North America GLP-1 Agonists for Obesity Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 37. US GLP-1 Agonists for Obesity Revenue (2020-2031) & (US$ Million)
 Figure 38. Canada GLP-1 Agonists for Obesity Revenue (2020-2031) & (US$ Million)
 Figure 39. Mexico GLP-1 Agonists for Obesity Revenue (2020-2031) & (US$ Million)
 Figure 40. Europe GLP-1 Agonists for Obesity Sales YoY (2020-2031) & (K Dose)
 Figure 41. Europe GLP-1 Agonists for Obesity Revenue YoY (2020-2031) & (US$ Million)
 Figure 42. Europe Top 5 Manufacturers GLP-1 Agonists for Obesity Sales Revenue (US$ Million) in 2024
 Figure 43. Europe GLP-1 Agonists for Obesity Sales Volume (K Dose) by Type (2020-2031)
 Figure 44. Europe GLP-1 Agonists for Obesity Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 45. Europe GLP-1 Agonists for Obesity Sales Volume (K Dose) by Application (2020-2031)
 Figure 46. Europe GLP-1 Agonists for Obesity Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 47. Germany GLP-1 Agonists for Obesity Revenue (2020-2031) & (US$ Million)
 Figure 48. France GLP-1 Agonists for Obesity Revenue (2020-2031) & (US$ Million)
 Figure 49. U.K. GLP-1 Agonists for Obesity Revenue (2020-2031) & (US$ Million)
 Figure 50. Italy GLP-1 Agonists for Obesity Revenue (2020-2031) & (US$ Million)
 Figure 51. Russia GLP-1 Agonists for Obesity Revenue (2020-2031) & (US$ Million)
 Figure 52. Asia-Pacific GLP-1 Agonists for Obesity Sales YoY (2020-2031) & (K Dose)
 Figure 53. Asia-Pacific GLP-1 Agonists for Obesity Revenue YoY (2020-2031) & (US$ Million)
 Figure 54. Asia-Pacific Top 8 Manufacturers GLP-1 Agonists for Obesity Sales Revenue (US$ Million) in 2024
 Figure 55. Asia-Pacific GLP-1 Agonists for Obesity Sales Volume (K Dose) by Type (2020- 2031)
 Figure 56. Asia-Pacific GLP-1 Agonists for Obesity Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 57. Asia-Pacific GLP-1 Agonists for Obesity Sales Volume (K Dose) by Application (2020-2031)
 Figure 58. Asia-Pacific GLP-1 Agonists for Obesity Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 59. Indonesia GLP-1 Agonists for Obesity Revenue (2020-2031) & (US$ Million)
 Figure 60. Japan GLP-1 Agonists for Obesity Revenue (2020-2031) & (US$ Million)
 Figure 61. South Korea GLP-1 Agonists for Obesity Revenue (2020-2031) & (US$ Million)
 Figure 62. China Taiwan GLP-1 Agonists for Obesity Revenue (2020-2031) & (US$ Million)
 Figure 63. India GLP-1 Agonists for Obesity Revenue (2020-2031) & (US$ Million)
 Figure 64. Central and South America GLP-1 Agonists for Obesity Sales YoY (2020-2031) & (K Dose)
 Figure 65. Central and South America GLP-1 Agonists for Obesity Revenue YoY (2020-2031) & (US$ Million)
 Figure 66. Central and South America Top 5 Manufacturers GLP-1 Agonists for Obesity Sales Revenue (US$ Million) in 2024
 Figure 67. Central and South America GLP-1 Agonists for Obesity Sales Volume (K Dose) by Type (2021-2031)
 Figure 68. Central and South America GLP-1 Agonists for Obesity Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 69. Central and South America GLP-1 Agonists for Obesity Sales Volume (K Dose) by Application (2020-2031)
 Figure 70. Central and South America GLP-1 Agonists for Obesity Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 71. Brazil GLP-1 Agonists for Obesity Revenue (2020-2025) & (US$ Million)
 Figure 72. Argentina GLP-1 Agonists for Obesity Revenue (2020-2025) & (US$ Million)
 Figure 73. Middle East, and Africa GLP-1 Agonists for Obesity Sales YoY (2020-2031) & (K Dose)
 Figure 74. Middle East and Africa GLP-1 Agonists for Obesity Revenue YoY (2020-2031) & (US$ Million)
 Figure 75. Middle East and Africa Top 5 Manufacturers GLP-1 Agonists for Obesity Sales Revenue (US$ Million) in 2024
 Figure 76. Middle East and Africa GLP-1 Agonists for Obesity Sales Volume (K Dose) by Type (2021-2031)
 Figure 77. South America GLP-1 Agonists for Obesity Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 78. Middle East and Africa GLP-1 Agonists for Obesity Sales Volume (K Dose) by Application (2020-2031)
 Figure 79. Middle East and Africa GLP-1 Agonists for Obesity Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 80. GCC Countries GLP-1 Agonists for Obesity Revenue (2020-2025) & (US$ Million)
 Figure 81. Turkey GLP-1 Agonists for Obesity Revenue (2020-2025) & (US$ Million)
 Figure 82. Egypt GLP-1 Agonists for Obesity Revenue (2020-2025) & (US$ Million)
 Figure 83. South Africa GLP-1 Agonists for Obesity Revenue (2020-2025) & (US$ Million)
 Figure 84. GLP-1 Agonists for Obesity Industry Chain Mapping
 Figure 85. Regional GLP-1 Agonists for Obesity Manufacturing Base Distribution (%)
 Figure 86. Global GLP-1 Agonists for Obesity Production Market Share by Region (2020-2031)
 Figure 87. GLP-1 Agonists for Obesity Production Process
 Figure 88. Regional GLP-1 Agonists for Obesity Production Cost Structure
 Figure 89. Channels of Distribution (Direct Vs Distribution)
 Figure 90. Bottom-up and Top-down Approaches for This Report
 Figure 91. Data Triangulation
 Figure 92. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

Global GLP 1 Agonist Injection Market Research Report 2024
Global Oral GLP 1 Agonist Market Research Report 2024
Global Glucagon Like Peptide 1 GLP 1 Agonists Market Research Report 2025
Global Antidiabetic Glucagon like Peptide 1 Agonists Market Research Report 2025
Global Glucagon like peptide 1 GLP 1 based Therapies Market Research Report 2025
Global GLP 1 Agonists for the Treatment of both Diabetes and Obesity Market Research Report 2024
GLP Analogs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global GLP 1 Receptor Agonist Drugs Market Research Report 2024
GLP 1 for Weight Loss Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global GLP 1 Weight Loss Drug Market Research Report 2024
Global Liraglutide for The Treatment of Diabetes and Obesity Market Research Report 2024
Global GLP 1 Receptor Antagonist Market Research Report 2024
GLP 1 Analogues Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global GLP 1 Drug Peptide API Market Research Report 2024
Global GLP 1 Weight Loss Pill Market Research Report 2024
Global GLP 1 Weight Loss Injection Market Research Report 2024
Global GLP 1 Drugs Market Research Report 2024
Global GLP 1 based Therapy Market Research Report 2024
Global GLP 1RA based Therapy for Obesity Market Research Report 2024
Global GLP 1RA Therapy Market Research Report 2024

RELATED REPORTS

Global GLP-1 Agonists for Obesity Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-6Q17184
Tue Nov 11 00:00:00 UTC 2025

Add to Cart

Global Digital Health For Obesity Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-9G17354
Wed Nov 05 00:00:00 UTC 2025

Add to Cart

Global Bariatric Surgical Procedures Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-36T5954
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Obesity Management Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-37J2827
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions